Mga Batayang Estadistika
| CIK | 1522860 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Acutus Medical, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| March 24, 2025 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of Acutus Medical, Inc. The following is a list of subsidiaries of the Company as of December 31, 2024, omitting subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary as defined by Rule 1-02(w) of Regulation S-X. Name of Subsidiary Jurisdiction of Incorporation or Organization Acutus Medical, N.V. Belgium |
|
| March 24, 2025 |
Acutus Medical, Inc. Consolidated Balance Sheets Press Release Exhibit 99.1 Acutus Medical Reports Full Year 2024 Financial Results CARLSBAD, Calif., March 24, 2025 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the full year of 2024. Recent Highlights: •2024 Revenue from Continuing Operations of $20.2 million grew 181% year-over-year, from $7.2 million last year. •Operating loss for co |
|
| March 24, 2025 |
Acutus Medical, Inc. Compensation Recoupment Policy ACUTUS MEDICAL, INC. COMPENSATION RECOUPMENT POLICY This Acutus Medical Inc. Compensation Recoupment Policy (“Policy”) has been adopted by the Board of Directors (the “Board”) of Acutus Medical, Inc. (the “Company”) on May 17, 2023. This Policy provides for the recoupment of certain executive compensation in the event of an accounting restatement resulting from material noncompliance with financia |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-394 |
|
| March 24, 2025 |
ACUTUS MEDICAL, INC. INSIDER TRADING POLICY (Effective as of August 5, 2020) The Board of Directors (the “Board”) of Acutus Medical, Inc. (together with its affiliates and subsidiaries, the “Company,” “we,” “our,” or “Acutus”) has adopted this Insider Trading Policy (the “Policy”) in order to take an active role in the prevention of insider trading violations by our officers, directors, employees |
|
| March 24, 2025 |
Description of the Registrant’s Securities Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK The following summary describes our capital stock and the material provisions of our amended and restated certificate of incorporation, our Certificate of Designation of Preferences, Rights and Limitations of our Series A Common Equivalent Preferred Stock, par value $0.001 per share, our amended and restated bylaws, the amended and restated investors rights |
|
| March 24, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2025 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| January 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 333-266804 ACUTUS MEDICAL, INC. (Exact name of Registrant as specified in it |
|
| January 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2025 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 21, 2025 |
As filed with the Securities and Exchange Commission on January 21, 2025. As filed with the Securities and Exchange Commission on January 21, 2025. Registration Statement No. 333-241143 Registration Statement No. 333-254799 Registration Statement No. 333-262467 Registration Statement No. 333-264004 Registration Statement No. 333-270811 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO Form S-8 Registration Statemen |
|
| January 21, 2025 |
Exhibit 10.3 WARRANT TERMINATION AGREEMENT THIS WARRANT TERMINATION AGREEMENT, dated as of January 21, 2025 (this “Agreement”) is entered into by and between Acutus Medical, Inc. a Delaware corporation (the “Company”), Deerfield Partners, L.P. (“Deerfield Partners”) and Deerfield Private Design Fund III, L.P. (“DPD III” and together with Deerfield Partners, each, a “Warrant Holder” and together, t |
|
| January 21, 2025 |
As filed with the Securities and Exchange Commission on January 21, 2025. As filed with the Securities and Exchange Commission on January 21, 2025. Registration Statement No. 333-241143 Registration Statement No. 333-254799 Registration Statement No. 333-262467 Registration Statement No. 333-264004 Registration Statement No. 333-270811 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO Form S-8 Registration Statemen |
|
| January 21, 2025 |
Exhibit 10.1 AMENDMENT NO. 5 TO AMENDED AND RESTATED CREDIT AGREEMENT This AMENDMENT NO. 5 TO AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”), dated as of January 21, 2025, is entered into by and between Acutus Medical, Inc. (the “Borrower” or the “Company”), and Deerfield Partners, L.P. (“Deerfield Partners”) and Deerfield Private Design Fund III, L.P. (“DPD III” and, together with Deerf |
|
| January 21, 2025 |
As filed with the Securities and Exchange Commission on January 21, 2025. As filed with the Securities and Exchange Commission on January 21, 2025. Registration Statement No. 333-241143 Registration Statement No. 333-254799 Registration Statement No. 333-262467 Registration Statement No. 333-264004 Registration Statement No. 333-270811 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO Form S-8 Registration Statemen |
|
| January 21, 2025 |
As filed with the Securities and Exchange Commission on January 21, 2025. POS AM 1 dp223620posam-268730.htm FORM POS AM As filed with the Securities and Exchange Commission on January 21, 2025. Registration Statement No. 333-266804 Registration Statement No. 333-268730 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO Form S-3 Registration Statement No. 333-266804 Form S-3 Registration Statement No. 333-268730 UNDE |
|
| January 21, 2025 |
Exhibit 10.2 CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of January 21, 2025 (this “Agreement”), is entered into by and among Deerfield Partners, L.P. (“Deerfield Partners”), Deerfield Private Design Fund III, L.P. (“DPD III”) and Acutus Medical, Inc. (“Acutus”, and together with Deerfield Partners and DPD III, each a “Party” and together, the “Parties”). REC |
|
| January 21, 2025 |
As filed with the Securities and Exchange Commission on January 21, 2025. POS AM 1 dp223619posam-266804.htm FORM POS AM As filed with the Securities and Exchange Commission on January 21, 2025. Registration Statement No. 333-266804 Registration Statement No. 333-268730 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO Form S-3 Registration Statement No. 333-266804 Form S-3 Registration Statement No. 333-268730 UNDE |
|
| January 21, 2025 |
As filed with the Securities and Exchange Commission on January 21, 2025. As filed with the Securities and Exchange Commission on January 21, 2025. Registration Statement No. 333-241143 Registration Statement No. 333-254799 Registration Statement No. 333-262467 Registration Statement No. 333-264004 Registration Statement No. 333-270811 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO Form S-8 Registration Statemen |
|
| January 21, 2025 |
Exhibit 10.4 REGISTRATION RIGHTS TERMINATION AGREEMENT This Registration Rights Termination Agreement (this “Agreement”) is entered into as of January 21, 2025 by and among Deerfield Partners, L.P. (“Deerfield Partners”), Deerfield Private Design Fund III, L.P. (“DPD III” and, together with Deerfield Partners, the “Deerfield Funds”) and Acutus Medical, Inc., a Delaware corporation (the “Company”). |
|
| January 21, 2025 |
As filed with the Securities and Exchange Commission on January 21, 2025. As filed with the Securities and Exchange Commission on January 21, 2025. Registration Statement No. 333-241143 Registration Statement No. 333-254799 Registration Statement No. 333-262467 Registration Statement No. 333-264004 Registration Statement No. 333-270811 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO Form S-8 Registration Statemen |
|
| December 16, 2024 |
AFIB / Acutus Medical, Inc. / Flynn James E - SC 13D/A Activist Investment SC 13D/A 1 d780413dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* Acutus Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 005111109 (CUSIP Number) Deerfield Management Company, L.P. Attn: Legal Department 345 Park Avenue, 12t |
|
| December 4, 2024 |
Acutus Medical Announces Operational Downsizing Exhibit 99.1 Press Release Acutus Medical Announces Operational Downsizing CARLSBAD, Calif., December 4, 2024 (GLOBE NEWSWIRE) – Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), today announced a realignment of resources and operational downsizing. Dr. Shaden Marzouk, Chairperson of the Board of Directors of Acutus, commented, “Following an extensive strategic review by the Company |
|
| December 4, 2024 |
Consulting Agreement between the Company and Takeo Mukai Exhibit 10.1 ACUTUS MEDICAL, INC. CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) is effective as of February 1, 2025 (the “Effective Date”) by and between Acutus Medical, Inc., a Delaware corporation with its principal place of business at 2210 Faraday Ave., Suite 100, Carlsbad, CA 92008 (the “Company”), and Takeo Mukai, an individual (“Consultant”) (each herein referred to indi |
|
| December 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2024 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 15, 2024 |
Financial Statements and Exhibits, Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 15, 2024 |
Exhibit 10.1 AMENDMENT NO. 4 TO AMENDED AND RESTATED CREDIT AGREEMENT This AMENDMENT NO. 4 TO AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”), dated as of November 13, 2024 (this “Fourth Amendment Effective Date”), is entered into by and between Acutus Medical, Inc. (the “Borrower” or the “Company”), and Deerfield Partners, L.P. (“Deerfield Partners”) and Deerfield Private Design Fund III |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 14, 2024 |
Acutus Medical, Inc. Consolidated Balance Sheets Press Release Exhibit 99.1 Acutus Medical Reports Third Quarter and Year-To-Date 2024 Financial Results CARLSBAD, Calif., November 14, 2024 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the third quarter and year-to-date of 2024. Recent Highlights: •Third quarter revenue from Continuing Operations of $5.3 million grew 156% year-over-year |
|
| November 14, 2024 |
AFIB / Acutus Medical, Inc. / LYTTON LAURENCE W Passive Investment SC 13G/A 1 afib13ga1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Acutus Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 005111109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| November 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 17, 2024 |
Exhibit 10.1 [***] = Certain information contained in this document, marked by brackets, has been omitted because it is both not material and is the type of information that the Company treats as private or confidential. CONFIDENTIAL SETTLEMENT AGREEMENT AND RELEASE THIS CONFIDENTIAL SETTLEMENT AGREEMENT AND RELEASE (the “Agreement”) is entered into and effective as of the date it has been fully e |
|
| October 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2024 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 8, 2024 |
Acutus Medical, Inc. Consolidated Balance Sheets Press Release Exhibit 99.1 Acutus Medical Reports Second Quarter and Year-To-Date 2024 Financial Results CARLSBAD, Calif., August 8, 2024 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the second quarter and year-to-date of 2024. Recent Highlights: •Second quarter revenue from Continuing Operations of $4.1 million grew 172% year-over-year |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001 |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 17, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2024 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 17, 2024 |
AFIB / Acutus Medical, Inc. / LYTTON LAURENCE W Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Acutus Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 005111109 (CUSIP Number) May 9, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| May 9, 2024 |
Press Release Exhibit 99.1 Acutus Medical Reports First Quarter 2024 Financial Results CARLSBAD, Calif., May 9, 2024 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the first quarter of 2024. Recent Highlights: •First quarter revenue from Continuing Operations of $3.6 million grew 192% year-over-year, from $1.2 million in the same quarter |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00 |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2024 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| April 25, 2024 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 1, 2024 |
Acutus Medical, Inc. Compensation Recoupment Policy Exhibit 97.1 ACUTUS MEDICAL, INC. COMPENSATION RECOUPMENT POLICY This Acutus Medical Inc. Compensation Recoupment Policy (“Policy”) has been adopted by the Board of Directors (the “Board”) of Acutus Medical, Inc. (the “Company”) on May 17, 2023. This Policy provides for the recoupment of certain executive compensation in the event of an accounting restatement resulting from material noncompliance |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-394 |
|
| April 1, 2024 |
Acutus Medical Reports Fourth Quarter and Full Year 2023 Financial Results Press Release Exhibit 99.1 Acutus Medical Reports Fourth Quarter and Full Year 2023 Financial Results CARLSBAD, Calif., April 1, 2024 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB) today reported results for the fourth quarter and full year ended December 31,2023. Recent Highlights: •Announced strategic realignment of resources and corporate restructuring on Nov |
|
| April 1, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 1, 2024 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of Acutus Medical, Inc. The following is a list of subsidiaries of the Company as of December 31, 2022, omitting subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary as defined by Rule 1-02(w) of Regulation S-X. Name of Subsidiary Jurisdiction of Incorporation Jurisdiction of Incorporation or Organization Acutus Medical, N.V. Belg |
|
| April 1, 2024 |
Description of the Registrant’s Securities Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK The following summary describes our capital stock and the material provisions of our amended and restated certificate of incorporation, our Certificate of Designation of Preferences, Rights and Limitations of our Series A Common Equivalent Preferred Stock, par value $0.001 per share, our amended and restated bylaws, the amended and restated investors rights |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 5, 2024 |
Exhibit 10.1 WAIVER AND AMENDMENT NO. 3 TO AMENDED AND RESTATED CREDIT AGREEMENT AND AMENDMENT TO LENDER WARRANTS AND WARRANT PURCHASE AGREEMENT This WAIVER AND AMENDMENT NO. 3 TO AMENDED AND RESTATED CREDIT AGREEMENT AND AMENDMENT TO LENDER WARRANTS AND WARRANT PURCHASE AGREEMENT (this “Amendment”), dated as of March 4, 2024 (this “Third Amendment Effective Date”), is entered into by and between |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2024 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2024 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 11, 2024 |
Consulting Agreement between the Registrant and David Roman ACUTUS MEDICAL, INC. CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) is effective as of January 9, 2024 (the “Effective Date”) by and between Acutus Medical, Inc., a Delaware corporation with its principal place of business at 2210 Faraday Ave., Suite 100, Carlsbad, CA 92008 (the “Company”), and David Roman, an individual (“Consultant”) (each herein referred to individually as a |
|
| January 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2024 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 13, 2023 |
AFIB / Acutus Medical Inc / Flynn James E Activist Investment SC 13D/A 1 e619058sc13d-acutus.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13D-2(a) (Amendment No. 6)* Acutus Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 005111109 (CUSIP Numb |
|
| November 13, 2023 |
, 2023, among the Company and the Lenders party thereto Exhibit 10.1 Execution Version AMENDMENT NO. 2 TO AMENDED AND RESTATED CREDIT AGREEMENT This AMENDMENT NO. 2 TO AMENDED AND RESTATED CREDIT AGREEMENT, dated as of November 8, 2023 (this “Amendment”), is entered into by and between Acutus Medical, Inc. (the “Borrower” or the “Company”), Deerfield Partners, L.P. (“Deerfield Partners”), Deerfield Private Design Fund III, L.P. (“DPD III” and, together |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 8, 2023 |
Acutus Medical Announces Strategic Realignment of Resources and Corporate Restructuring Exhibit 99.2 Press Release Acutus Medical Announces Strategic Realignment of Resources and Corporate Restructuring CARLSBAD, Calif., November 8, 2023 (GLOBE NEWSWIRE) – Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), today announced a realignment of resources and corporate restructuring. Scott Huennekens, Chairman of Acutus, commented, “Following an extensive strategic review by t |
|
| November 8, 2023 |
Acutus Medical Reports Third Quarter 2023 Financial Results Exhibit 99.1 Acutus Medical Reports Third Quarter 2023 Financial Results CARLSBAD, Calif., November 8, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB) today reported results for the third quarter of 2023. Recent Highlights: • Third quarter revenue of $5.2 million grew 44% year-over-year, led by strong growth in distribution revenue from sales of left-heart a |
|
| October 31, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2023 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 7, 2023 |
Execution Version AMENDMENT NO. 1 TO AMENDED AND RESTATED CREDIT AGREEMENT This AMENDMENT NO 1. TO AMENDED AND RESTATED CREDIT AGREEMENT, dated as of August 4, 2023 (this “Amendment”), is entered into by and between Acutus Medical, Inc. (the “Borrower”) and the Lenders party hereto, and acknowledged by Wilmington Trust, National Association, as Administrative Agent. WHEREAS, Borrower, the Lenders |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001 |
|
| August 7, 2023 |
Acutus Medical Reports Second Quarter 2023 Financial Results Press Release Exhibit 99.1 Acutus Medical Reports Second Quarter 2023 Financial Results CARLSBAD, Calif., August 7, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the second quarter of 2023. Recent Highlights: •Second quar |
|
| July 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2023 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM SD Specialized Disclosure Report Acutus Medical, Inc. |
|
| May 11, 2023 |
Acutus Medical Reports First Quarter 2023 Financial Results Press Release Exhibit 99.1 Acutus Medical Reports First Quarter 2023 Financial Results CARLSBAD, Calif., May 11, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the first quarter of 2023. Recent Highlights: •Reported revenu |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 11, 2023 |
Employment Agreement by and between Registrant and Tom Sohn, dated August 5, 2020 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made by and amongst Acutus Medical, Inc. |
|
| May 11, 2023 |
Employment Agreement by and between Registrant and Kevin Matthews, dated May 1, 2022 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made by and amongst Acutus Medical, Inc. |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00 |
|
| May 11, 2023 |
EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made by and amongst Acutus Medical, Inc. |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2023 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| April 27, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 27, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 20, 2023 |
Acutus Medical Announces Preliminary Unaudited First Quarter 2023 Results Exhibit 99.1 Press Release Acutus Medical Announces Preliminary Unaudited First Quarter 2023 Results Carlsbad, Calif. – April 20, 2023 – Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced preliminary unaudited results for the first quarter 2023 in addition to t |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2023 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 24, 2023 |
CALCULATION OF FILING FEE Form S-8 (Form type) Acutus Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (3) Fee Rate Amount of Registration Fee (4) Equity Common Stock, par value $0.001 per share Rule 4 |
|
| March 24, 2023 |
Description of the Registrant’s Securities Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK The following summary describes our capital stock and the material provisions of our amended and restated certificate of incorporation, our Certificate of Designation of Preferences, Rights and Limitations of our Series A Common Equivalent Preferred Stock, par value $0.001 per share, our amended and restated bylaws, the amended and restated investors rights |
|
| March 24, 2023 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of Acutus Medical, Inc. The following is a list of subsidiaries of the Company as of December 31, 2022, omitting subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary as defined by Rule 1-02(w) of Regulation S-X. Name of Subsidiary Jurisdiction of Incorporation or Organization Acutus Medical, N.V. Belgium Acutus Medical UK Limited |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39430 ACUTUS MEDICAL, |
|
| March 24, 2023 |
As filed with the Securities and Exchange Commission on March 23, 2023 As filed with the Securities and Exchange Commission on March 23, 2023 Registration No. |
|
| March 16, 2023 |
Acutus Medical Reports Fourth Quarter and Full Year 2022 Financial Results Press Release Exhibit 99.1 Acutus Medical Reports Fourth Quarter and Full Year 2022 Financial Results CARLSBAD, Calif., March 16, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the fourth quarter and full year ended Decemb |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| February 13, 2023 |
AFIB / Acutus Medical Inc / Capital World Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Acutus Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 005111109 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| January 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2023 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| January 9, 2023 |
Exhibit 99.1 Press Release Acutus Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Results and Appointment of Chief Financial Officer Carlsbad, Calif. – January 9, 2023 - Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced preliminary un |
|
| January 9, 2023 |
Employment Agreement by and between Registrant and Takeo Mukai EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made by and amongst Acutus Medical, Inc. |
|
| December 21, 2022 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-268730 PROSPECTUS $15,000,000 COMMON STOCK We may offer shares of common stock from time to time, up to an aggregate offering amount of $15,000,000, on terms to be determined at the time of offering. Our common stock is listed on The Nasdaq Global Select Market under the symbol “AFIB.” On December 19, 2022, the last reported sale price of our c |
|
| December 19, 2022 |
December 19, 2022 VIA EDGAR TRANSMISSION U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Abby Adams Re: Acutus Medical, Inc. Registration Statement on Form S-3 Registration No. 333-268730 Dear Ms. Adams: In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the eff |
|
| December 9, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-3 (Form Type) Acutus Medical, Inc. |
|
| December 9, 2022 |
As filed with the Securities and Exchange Commission on December 9, 2022 As filed with the Securities and Exchange Commission on December 9, 2022 Registration No. |
|
| December 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2022 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 10, 2022 |
Consulting Agreement between Registrant and Steve McQuillan ACUTUS MEDICAL, INC. CONSULTING AGREEMENT This Consulting Agreement (this ?Agreement?) is effective as of August 9, 2022 (the ?Effective Date?) by and between Acutus Medical, Inc., a Delaware corporation with its principal place of business at 2210 Faraday Ave., Suite 100, Carlsbad, CA 92008 (the ?Company?), and Steve McQuillan, an individual (?Consultant?) (each herein referred to individually as |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 10, 2022 |
Acutus Medical Reports Third Quarter 2022 Financial Results Exhibit 99.1 Press Release Acutus Medical Reports Third Quarter 2022 Financial Results Carlsbad, Calif. – November 10, 2022 – Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the third quarter of 2022. Recent Updates: •Reported revenue of $3.6 mill |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 3, 2022 |
Exhibit 99.1 Press Release Acutus Medical Achieves OEM Qualification Milestone in Sale of Left-Heart Access Portfolio to Medtronic Carlsbad, Calif. – November 3, 2022 – Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced that the Company has achieved the first m |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2022 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2022 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 22, 2022 |
Acutus Medical, Inc. 16,537,961 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-266804 PROSPECTUS Acutus Medical, Inc. 16,537,961 Shares of Common Stock This prospectus covers the offer and resale by the selling stockholders identified herein, from time to time in one or more offerings, of up to 16,537,961 shares of our common stock, par value $0.001 per share, which consist of (i) an aggregate of 5,296,772 shares of our c |
|
| August 17, 2022 |
CORRESP 1 filename1.htm August 17, 2022 VIA EDGAR TRANSMISSION U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Dorrie Yale Re: Acutus Medical, Inc. Registration Statement on Form S-3 Registration No. 333-266804 Dear Ms. Yale: In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request a |
|
| August 11, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 to CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 (June 30, 2022) Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdic |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001 |
|
| August 11, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-3 (Form Type) Acutus Medical, Inc. |
|
| August 11, 2022 |
Unaudited Pro Forma Condensed Consolidated Financial Information Exhibit 99.2 Unaudited Pro Forma Condensed Consolidated Financial Information Overview On June 30, 2022 (the ?Effective Date?), Acutus Medical, Inc. (?Acutus? or the ?Company?) completed its previously announced transaction with Medtronic, Inc. (together with its affiliates, ?Medtronic?), in accordance with the Asset Purchase Agreement (the ?Agreement?) executed on April 26, 2022, and pursuant to |
|
| August 11, 2022 |
As filed with the Securities and Exchange Commission on August 11, 2022 As filed with the Securities and Exchange Commission on August 11, 2022 Registration No. |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 11, 2022 |
Acutus Medical Reports Second Quarter 2022 Financial Results Exhibit 99.1 Press Release Acutus Medical Reports Second Quarter 2022 Financial Results Carlsbad, Calif. ? August 11, 2022 ? Acutus Medical, Inc. (?Acutus? or the ?Company?) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the second quarter of 2022. Recent Updates: ?Reported revenue of $4.1 mill |
|
| July 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2022 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 26, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2022 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 21, 2022 |
Acutus Medical Announces CEO Appointment and Preliminary Second Quarter Revenue Results Exhibit 99.1 Acutus Medical Announces CEO Appointment and Preliminary Second Quarter Revenue Results CARLSBAD, Calif., July 21, 2022 (GLOBE NEWSWIRE) - Acutus Medical, Inc. (?Acutus? or the ?Company?) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced that David Roman has been appointed President and Chief Ex |
|
| July 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2022 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 21, 2022 |
Amendment No. 1 to Employment Agreement by and between Registrant and David Roman Exhibit 10.1 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT This Amendment No. 1 to Employment Agreement (the ?Amendment?) is made by and amongst Acutus Medical, Inc. (the ?Company?), having its principal offices at 2210 Faraday Ave., Suite 100 Carlsbad, CA 92008, and David Roman (the ?Executive?), effective as of July 20, 2022. Whereas, the Company and the Executive are parties to that certain Employmen |
|
| July 5, 2022 |
AFIB / Acutus Medical Inc / Flynn James E Activist Investment SC 13D/A 1 e621810sc13da-am.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13D-2(a) (Amendment No. 5)* Acutus Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 005111109 (CUSIP Number) |
|
| July 1, 2022 |
Exhibit 99.2 Acutus Medical Completes First Closing of Transaction with Medtronic and Debt Refinancing to Fund Strategic Growth Priorities Carlsbad, Calif. ? July 1, 2022 ? Acutus Medical, Inc. (?Acutus? or the ?Company?) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the completion of the first of two cl |
|
| July 1, 2022 |
Form of Warrant for the issuance of warrants dated June 30, 2022 Exhibit 10.3 In accordance with Instruction 2 to Item 601 of Regulation S-K, below is a schedule setting forth details in which the omitted executed warrants differ from the form of warrant that follows: Holder Deerfield Partners, L.P. Deerfield Private Design Fund III, L.P. THIS WARRANT AND THE SECURITIES ISSUABLE IN CONNECTION HEREWITH HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, A |
|
| July 1, 2022 |
Exhibit 10.1 AMENDED AND RESTATED CREDIT AGREEMENT dated as of June 30, 2022 among ACUTUS MEDICAL, INC., as the Borrower, THE LENDERS FROM TIME TO TIME PARTY HERETO AND WILMINGTON TRUST, NATIONAL ASSOCIATION, as the Administrative Agent THE LOANS HEREUNDER ARE BEING ISSUED WITH ORIGINAL ISSUE DISCOUNT (?OID?) FOR U.S. FEDERAL INCOME TAX PURPOSES. THE ISSUE PRICE, AMOUNT OF OID, ISSUE DATE AND YIEL |
|
| July 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2022 (June 30, 2022) Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) ( |
|
| July 1, 2022 |
Unaudited Pro Forma Condensed Consolidated Financial Information Exhibit 99.1 Unaudited Pro Forma Condensed Consolidated Financial Information Overview On June 30, 2022, Acutus Medical, Inc. (?Acutus? or the ?Company?) completed the first closing (the ?First Closing?) in connection with its previously announced transaction with Medtronic, Inc. (together with its affiliates, ?Medtronic?), in accordance with the Asset Purchase Agreement (the ?Agreement?) executed |
|
| July 1, 2022 |
Exhibit 10.2 WARRANT PURCHASE AGREEMENT This Warrant Purchase Agreement (the ?Agreement?) is made as of June 30, 2022 (the ?Effective Date?) by and among Acutus Medical, Inc., a Delaware corporation (the ?Company?), and the persons and entities named on the Schedule of Purchasers attached hereto (individually, a ?Purchaser? and collectively, the ?Purchasers?). Capitalized terms used in this Agreem |
|
| July 1, 2022 |
Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of June 30, 2022, by and among Acutus Medical, Inc., a Delaware corporation (the ?Company?), Deerfield Partners, L.P. (?Deerfield Partners?) and Deerfield Private Design Fund III, L.P. (?DPD III? and, together with Deerfield Partners, the ?Lenders? and each a ?Lender?). WHEREAS: A. In connection w |
|
| June 28, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT (Amendment No. 1) Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2022 Acutus Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39430 45-1306615 (State or other jurisdiction of incorporati |
|
| June 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2022 (June 22, 2022) Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) |
|
| June 21, 2022 |
Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2022 Acutus Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39430 45-1306615 (State or other jurisdiction of incorporation) (Commission File |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| May 12, 2022 |
Acutus Medical Reports First Quarter 2022 Financial Results and CEO Transition Exhibit 99.1 Press Release Acutus Medical Reports First Quarter 2022 Financial Results and CEO Transition Carlsbad, Calif. ? May 12, 2022 ? Acutus Medical, Inc. (?Acutus? or the ?Company?) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the first quarter of 2022 and announced a leadership transi |
|
| May 12, 2022 |
Consulting Agreement between Registrant and Vince Burgess EX-10.2 3 afib-2022512xexhibit102.htm EX-10.2 ACUTUS MEDICAL, Inc. CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) is effective as of May 13, 2022 (the “Effective Date”) by and between Acutus Medical, Inc., a Delaware corporation with its principal place of business at 2210 Faraday Ave., Suite 100, Carlsbad, CA 92008 (the “Company”), and Vince Burgess, an individual (“Consultant” |
|
| May 12, 2022 |
Separation Agreement between Registrant and Vince Burgess May 12, 2022 Vincent Burgess 182 Andrew Avenue Encinitas, CA 92024 Re: Terms of Separation Dear Vincent: This letter confirms the agreement between you and Acutus Medical, Inc. |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00 |
|
| April 28, 2022 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 27, 2022 |
Commitment Letter dated April 26, 2022, by and between Registrant and the Commitment Parties Exhibit 10.2 Execution Version CONFIDENTIAL Deerfield Management Company, L.P. 345 Park Avenue South New York, New York 10010 April 26, 2022 Acutus Medical, Inc. 2210 Faraday Avenue, Suite 100 Carlsbad, CA 92008 Re: Commitment Letter $35.0 Million Senior Secured Term Loan Credit Facility Ladies and Gentlemen: You have advised the investment funds managed by Deerfield Management Company, L.P. (?Dee |
|
| April 27, 2022 |
Acutus Medical Announces Agreements to Fund Strategic Growth Priorities Exhibit 99.1 Acutus Medical Announces Agreements to Fund Strategic Growth Priorities Carlsbad, Calif. ? April 27, 2022 ? Acutus Medical, Inc. (?Acutus? or the ?Company?) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced a commitment letter from Deerfield Management Company (?Deerfield?), to refinance its exi |
|
| April 27, 2022 |
Asset Purchase Agreement dated April 26, 2022, by and among Medtronic, Inc. and Acutus Medical, Inc. Exhibit 2.1 ASSET PURCHASE AGREEMENT BY AND AMONG MEDTRONIC, INC. AND ACUTUS MEDICAL, INC. April 26, 2022 ASSET PURCHASE AGREEMENT THIS ASSET PURCHASE AGREEMENT (this ?Agreement?), dated as of April 26, 2022, is entered into by and among Medtronic, Inc., a Minnesota corporation (the ?Purchaser?), and Acutus Medical, Inc., a Delaware corporation (the ?Seller?). Capitalized terms used herein and not |
|
| April 27, 2022 |
EX-10.3 5 dp171628ex1003.htm EXHIBIT 10.3 Exhibit 10.3 2nd Amendment to the Global Alliance for Acutus Product Distribution Agreement This 2nd Amendment (“Amendment”) is made between: BIOTRONIK SE & Co. KG, Woermannkehre 1, 12359 Berlin, Germany (in the following referred to as “Biotronik”), and Acutus Medical, Inc. 2210 Faraday Ave Suite 100, Carlsbad 92008, California, U.S.A. (in the following r |
|
| April 27, 2022 |
Exhibit 10.1 Execution Version CONSENT This CONSENT (this ?Consent?) is made and entered into as of April 26, 2022 by ORBIMED ROYALTY OPPORTUNITIES II, LP, in its capacity as Origination Agent and a Lender (each as defined in the Credit Agreement) under the Credit Agreement (as defined below) and DEERFIELD PRIVATE DESIGN FUND III, L.P., in its capacity as a Lender, in favor of ACUTUS MEDICAL, INC. |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2022 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 27, 2022 |
AFIB / Acutus Medical Inc / Flynn James E Activist Investment SC 13D/A 1 e621597sc13da-am.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13D-2(a) (Amendment No. 4)* Acutus Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 005111109 (CUSIP Number) |
|
| March 31, 2022 |
2022 Inducement Equity Plan and forms of agreement thereunder Exhibit 99.1 ACUTUS MEDICAL, INC. 2022 INDUCEMENT EQUITY INCENTIVE PLAN (adopted on March 1, 2022) 1. Purpose of the Plan; Award Types and Eligibility. (a) Purpose of the Plan. The purpose of this Plan is to promote the success of the Company?s business and the interests of the Company?s stockholders by (i) providing an inducement material for certain individuals to enter into employment with the |
|
| March 31, 2022 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) ACUTUS MEDICAL, INC. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Title of each Class of Securities to be Registered Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Unit (3) Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registra |
|
| March 31, 2022 |
As filed with the Securities and Exchange Commission on March 30, 2022 As filed with the Securities and Exchange Commission on March 30, 2022 Registration No. |
|
| March 30, 2022 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of Acutus Medical, Inc. The following is a list of subsidiaries of the Company as of December 31, 2021, omitting subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary as defined by Rule 1-02(w) of Regulation S-X. Name of Subsidiary Jurisdiction of Incorporation or Organization Acutus Medical, N.V. Belgium Acutus Medical UK Limited |
|
| March 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-394 |
|
| March 30, 2022 |
Acutus Medical Reports Fourth Quarter and Full Year 2021 Financial Results Exhibit 99.1 Press Release Acutus Medical Reports Fourth Quarter and Full Year 2021 Financial Results Carlsbad, Calif. ? March 30, 2022 ? Acutus Medical, Inc. (?Acutus? or the ?Company?) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the fourth quarter and full year ended December 31, 2021. Rec |
|
| March 30, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2022 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 30, 2022 |
Description of the Registrant’s Securities Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK The following summary describes our capital stock and the material provisions of our amended and restated certificate of incorporation, our Certificate of Designation of Preferences, Rights and Limitations of the Series A Common Equivalent Preferred Stock, par value $0.001 per share, our amended and restated bylaws, the amended and restated investors rights |
|
| February 14, 2022 |
AFIB / Acutus Medical Inc / Advent Life Sciences LLP - FORM SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Acutus Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 005111109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| February 11, 2022 |
AFIB / Acutus Medical Inc / Capital World Investors - SEC SCHEDULE 13G Passive Investment SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Acutus Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 005111109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| February 11, 2022 |
AFIB / Acutus Medical Inc / Kerrisdale Advisers, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 1, 2022 |
Acutus Medical, Inc. 2020 Equity Incentive Plan Exhibit 99.1 ACUTUS MEDICAL, INC. 2020 EQUITY INCENTIVE PLAN 1. Purposes of the Plan; Award Types. (a) Purposes of the Plan. The purposes of this Plan are to attract and retain personnel for positions with the Company Group, to provide additional incentive to Employees, Directors, and Consultants (collectively, ?Service Providers?), and to promote the success of the Company?s business. (b) Award T |
|
| February 1, 2022 |
As filed with the Securities and Exchange Commission on February 1, 2022 As filed with the Securities and Exchange Commission on February 1, 2022 Registration No. |
|
| February 1, 2022 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Acutus Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.001 |
|
| January 19, 2022 |
Exhibit 99.1 Press Release Acutus Medical Announces Restructuring and Preliminary, Unaudited Fourth Quarter and Full Year 2021 Revenue Carlsbad, Calif. ? January 19, 2022 ? Acutus Medical, Inc. (?Acutus? or the ?Company?) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced a corporate restructuring as well as |
|
| January 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2022 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 18, 2021 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated November 18, 2021, with respect to the ordinary shares of Acutus Medical, Inc. |
|
| November 18, 2021 |
AFIB / Acutus Medical Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 3 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) Acutus Medical, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 065111109 (CUSIP Number) OrbiMed Advisors LLC OrbiMed ROF II LLC OrbiMed Capital GP IV LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Nam |
|
| November 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2021 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 12, 2021 |
Acutus Medical Reports Third Quarter 2021 Financial Results Exhibit 99.1 Press Release Acutus Medical Reports Third Quarter 2021 Financial Results Carlsbad, Calif. ? November 11, 2021 ? Acutus Medical, Inc. (?Acutus? or the ?Company?) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the third quarter of 2021. Recent Highlights: ?Significant progress was a |
|
| November 12, 2021 |
EX-99.2 3 afib-20211112xexhibit992.htm EX-99.2 Exhibit 99.2 Press Release REFINITIV STREETEVENTS EDITED TRANSCRIPT Q3 2021 Acutus Medical Inc Earnings Call EVENT DATE/TIME: NOVEMBER 11, 2021 / 9:30PM GMT . REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us ©2021 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is proh |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| August 31, 2021 |
EX-99.1 2 ss464017ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated August 31, 2021, with respect to the ordinary shares of Acutus Medical, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the |
|
| August 31, 2021 |
AFIB / Acutus Medical Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 2 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Acutus Medical, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 065111109 (CUSIP Number) OrbiMed Advisors LLC OrbiMed ROF II LLC OrbiMed Capital GP IV LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Nam |
|
| August 26, 2021 |
AFIB / Acutus Medical Inc / Flynn James E Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13D-2(a) (Amendment No. 3)* Acutus Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 005111109 (CUSIP Number) Deerfield Management Company, L |
|
| August 23, 2021 |
Exhibit 3.1 ACUTUS MEDICAL, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A COMMON STOCK EQUIVALENT CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151(g) OF THE DELAWARE GENERAL CORPORATION LAW ACUTUS MEDICAL, INC., a Delaware corporation (the ?Company?), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the ?DGCL?), does |
|
| August 23, 2021 |
Exhibit 10.1 EXCHANGE AGREEMENT This EXCHANGE AGREEMENT (including the schedules, annexes and exhibits hereto, this ?Agreement?), dated as of August 23, 2021, is entered into by and among Acutus Medical, Inc., a Delaware corporation (the ?Company?), Deerfield Private Design Fund III, L.P. (?DPD III?), Deerfield Partners, L.P. (?DP? and, together with DPD IV, the ?Holders? and each a ?Holder?). REC |
|
| August 23, 2021 |
Exhibit 10.2 EXCHANGE AGREEMENT This EXCHANGE AGREEMENT (including the schedules, annexes and exhibits hereto, this ?Agreement?), dated as of August 23, 2021, is entered into by and among Acutus Medical, Inc., a Delaware corporation (the ?Company?), OrbiMed Private Investments IV, LP (?OrbiMed PI IV?) and OrbiMed Royalty Opportunities II, LP (?OrbiMed RO II? and, together with OrbiMed PI IV, the ? |
|
| August 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2021 Acutus Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39430 45-1306615 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001 |
|
| August 12, 2021 |
Acutus Medical Reports Second Quarter 2021 Financial Results Exhibit 99.1 Press Release Acutus Medical Reports Second Quarter 2021 Financial Results Carlsbad, Calif. ? August 12, 2021 ? Acutus Medical, Inc. (?Acutus? or the ?Company?) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the second quarter of 2021. Recent Highlights: ?Reported revenue of $4.7 m |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 12, 2021 |
Acutus Medical Appoints Niamh Pellegrini to Board of Directors Exhibit 99.2 Press Release Acutus Medical Appoints Niamh Pellegrini to Board of Directors Carlsbad, Calif., August 12, 2021 ? Acutus Medical (?Acutus?) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the appointment of Niamh Pellegrini to the Company's Board of Directors, effective August 10, 2021. Ms. Pel |
|
| July 21, 2021 |
AFIB / Acutus Medical Inc / Kerrisdale Advisers, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| July 21, 2021 |
AFIB / Acutus Medical Inc / Flynn James E Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13D-2(a) (Amendment No. 2)* Acutus Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 005111109 (CUSIP Number) David Clark Elliot Press Deerfi |
|
| July 15, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-257844 5,500,000 Shares Common Stock We are offering 5,500,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Select Market under the symbol ?AFIB.? On July 14, 2021, the last reported sale price of our common stock on The Nasdaq Global Select Market was $15.05 per share. We are an emerging growth |
|
| July 14, 2021 |
AFIB / Acutus Medical Inc / ORBIMED ADVISORS LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Acutus Medical, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 065111109 (CUSIP Number) OrbiMed Advisors LLC OrbiMed ROF II LLC OrbiMed Capital GP IV LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Nam |
|
| July 14, 2021 |
EX-99.1 2 ss372701ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated July 13, 2021, with respect to the ordinary shares of Acutus Medical, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the un |
|
| July 13, 2021 |
AFIB / Acutus Medical Inc / Flynn James E Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13D-2(a) (Amendment No. 1)* Acutus Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 005111109 (CUSIP Number) David Clark Elliot Press Deerfi |
|
| July 12, 2021 |
Acutus Medical Reports Preliminary Unaudited Second Quarter 2021 Financial Results EX-99.1 2 afib-20210708xexhibit991.htm EX-99.1 Exhibit 99.1 Press Release Acutus Medical Reports Preliminary Unaudited Second Quarter 2021 Financial Results Carlsbad, Calif. – July 12, 2021 – Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported preliminary unaudit |
|
| July 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2021 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 12, 2021 |
July 12, 2021 VIA EDGAR TRANSMISSION AND FEDEX U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Margaret Schwartz Re: Acutus Medical, Inc. Registration Statement on Form S-1 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective da |
|
| July 12, 2021 |
Form of Letter Agreement Relating to Exchange of Common Stock for Series A Preferred Stock EX-10.25 5 d187581dex1025.htm EX-10.25 Exhibit 10.25 ACUTUS MEDICAL, INC. July 11, 2021 [Investors] [Investor Address] Ladies and Gentlemen: Reference is made to a contemplated underwritten offering (the “Offering”) by Acutus Medical, Inc. (the “Company”) of shares of its common stock, par value $0.001 per share (the “Common Stock”) pursuant to a registration statement on Form S-1 (the “Registrati |
|
| July 12, 2021 |
As filed with the Securities and Exchange Commission on July 12, 2021 S-1 Table of Contents As filed with the Securities and Exchange Commission on July 12, 2021 Registration No. |
|
| July 12, 2021 |
July 12, 2021 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| July 12, 2021 |
Feasibility and Development Agreement, by and between Biotronik SE & Co. KG and Acutus Medical, Inc. EX-10.24 4 d187581dex1024.htm EX-10.24 Exhibit 10.24 Feasibility and Development Agreement by and between Biotronik SE & Co. KG (Biotronik) Woermannkehre 1, 12359 Berlin, Germany and Acutus Medical, Inc. (Acutus) 2210 Faraday Ave Suite 100, Carlsbad 92008, California, U.S.A. (Biotronik and Acutus together the Parties and each a Party) Page 1 of 32 Table of Contents 1. Definitions and Interpretatio |
|
| July 12, 2021 |
Exhibit 1.1 Acutus Medical, Inc. [●] Shares of Common Stock, par value $0.001 per share Underwriting Agreement [●], 2021 Goldman Sachs & Co. LLC As Representative of the several Underwriters listed in Schedule 1 hereto Ladies and Gentlemen: Acutus Medical, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwri |
|
| June 21, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2021 Acutus Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39430 45-1306615 (State or other jurisdiction of incorporation) (Commission File |
|
| June 7, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2021 Acutus Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39430 45-1306615 (State or other jurisdiction of incorporation) (Commission File |
|
| May 27, 2021 |
Table of Contents Confidential Treatment Requested by Acutus Medical, Inc. Pursuant to 17 C.F.R. Section 200.83 As confidentially submitted to the Securities and Exchange Commission on May 27, 2021 This draft registration statement has not been filed publicly with the Securities and Exchange Commission and all information contained herein remains strictly confidential. Registration No. 333- SECURI |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39430 ACUTUS MED |
|
| May 12, 2021 |
Acutus Medical Reports First Quarter 2021 Financial Results 5/12/21 Exhibit 99.1 Press Release Acutus Medical Reports First Quarter 2021 Financial Results Carlsbad, Calif. ? May 12, 2021 ? Acutus Medical, Inc. (?Acutus? or the ?Company?) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the first quarter of 2021. Recent Highlights: ? Reported revenue of $3 |
|
| May 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 afib-8k20210331.htm AFIB-8-K Q1 EARNINGS RELEASE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2021 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 29, 2021 |
As filed with the Securities and Exchange Commission on March 26, 2021 Registration No. |
|
| March 19, 2021 |
Amendment No. 2 and Waiver to the Credit Agreement, dated October 21, 2020 EX-10.25 5 afib-ex1025508.htm EX-10.25 Exhibit 10.25 Execution Version AMENDMENT NO. 2 AND WAIVER This AMENDMENT NO. 2 AND WAIVER (this “Amendment”) is made and entered into as of October 21, 2020 by ORBIMED ROYALTY OPPORTUNITIES II, LP, in its capacity as Origination Agent and a Lender (each as defined in the Credit Agreement) under the Credit Agreement (as defined below) and DEERFIELD PRIVATE DE |
|
| March 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39430 ACUTUS MEDICAL, |
|
| March 19, 2021 |
Amendment No. 1 to Credit Agreement, dated June 7, 2019 EX-10.24 4 afib-ex1024509.htm EX-10.24 Execution Version Exhibit 10.24 FIRST AMENDMENT TO CREDIT AGREEMENT This FIRST AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of June 7, 2019, by and among ACUTUS MEDICAL, INC., a Delaware corporation (the “Borrower”), orbimed royalty opportunities ii, lp, in its capacity as Origination Agent under the Credit Agreement (the “Orig |
|
| March 19, 2021 |
Subsidiaries of the Registrant EX-21.1 6 afib-ex211507.htm EX-21.1 Exhibit 21.1 Subsidiaries of Acutus Medical, Inc. The following is a list of subsidiaries of the Company as of December 31, 2020, omitting subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary as defined by Rule 1-02(w) of Regulation S-X. Name of Subsidiary Jurisdiction of Incorporation or Organization Acutus Medical, N.V |
|
| March 19, 2021 |
Employment Agreement between Registrant and David Roman Exhibit 10.22 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is made by and amongst Acutus Medical, Inc. (the ?Company?), having its principal offices at 2210 Faraday Ave., Suite 100 Carlsbad, CA 92008, and David Roman (the ?Executive?), effective as of March 1, 2021 (the ?Effective Date?). Whereas, the Company desires to employ the Executive in the position of Senior Vice Presi |
|
| March 19, 2021 |
Description of the Registrant’s Securities EX-4.3 2 afib-ex43742.htm EX-4.3 Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK The following summary describes our capital stock and the material provisions of our amended and restated certificate of incorporation and our amended and restated bylaws, the amended and restated investors rights agreement to which we and certain of our stockholders are parties, and of the Delaware General Corporation Law, |
|
| March 18, 2021 |
EX-99.2 3 afib-ex99219.htm EX-99.2 Exhibit 99.2 Press Release Acutus Medical Board Appoints John Sheridan as a New Director New Board Appointment Brings Demonstrated Leadership in the Medical Device Industry CARLSBAD, Calif., March 18, 2021 Acutus Medical (Nasdaq: AFIB) today announced the appointment of John Sheridan to the Company's board of directors effective March 17, 2021. Since March 2019, |
|
| March 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2021 Acutus Medical, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| March 18, 2021 |
Acutus Medical Reports Fourth Quarter and Full Year 2020 Financial Results EX-99.1 2 afib-ex9916.htm EX-99.1 3/17/21 Exhibit 99.1 Press Release Acutus Medical Reports Fourth Quarter and Full Year 2020 Financial Results Carlsbad, Calif. – March 18, 2021 – Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the fourth quarter and full year end |
|
| February 11, 2021 |
SC 13G 1 tm216199d1sc13g.htm SC 13G Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Acutus Medical, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of |
|
| February 11, 2021 |
Exhibit 99 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. |
|
| February 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Acutus Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 005111109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2021 ACUTUS MEDICAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 9, 2021 |
Acutus Medical, Inc. Appoints New Chief Financial Officer and New Board Member Exhibit 99.1 Press Release Acutus Medical, Inc. Appoints New Chief Financial Officer and New Board Member •David Roman appointed Chief Financial Officer •Daniella Cramp to join Board of Directors CARLSBAD, Calif., February 9, 2021, Acutus Medical (Nasdaq: AFIB), today announced the appointment of David Roman as the company’s Chief Financial Officer, effective March 1, 2021. In addition, Daniella C |
|
| January 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2021 ACUTUS MEDICAL, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39430 45-1306615 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 13, 2021 |
Guided Ablation Therapy for Cardiac Arrhythmias Exhibit 99.2 Legal Disclaimer 2 This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, availability of funding, ability to maintain ex |
|
| January 13, 2021 |
Acutus Medical Reports Preliminary, Unaudited Fourth Quarter and Full Year 2020 Results Exhibit 99.1 Press Release Acutus Medical Reports Preliminary, Unaudited Fourth Quarter and Full Year 2020 Results Carlsbad, Calif. – January 13, 2021 – Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported preliminary unaudited revenue results for the quarter and full year ended D |
|
| November 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39430 ACUTUS |
|
| November 12, 2020 |
Acutus Medical Reports Third Quarter 2020 Results EX-99.1 Exhibit 99.1 Press Release Acutus Medical Reports Third Quarter 2020 Results Carlsbad, Calif. – November 12, 2020 – Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the third quarter of 2020. Recent Highlights: • Reported revenue of $3.2 million in the thir |
|
| November 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2020 Acutus Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39430 45-1306615 (State or other jurisdiction of incorporation) (Co |
|
| September 18, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001 |
|
| September 17, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2020 Acutus Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39430 45-1306615 (State or other jurisdiction of incorporation) (C |
|
| September 17, 2020 |
Acutus Medical Reports Second Quarter 2020 Financial Results EX-99.1 Exhibit 99.1 Press Release Acutus Medical Reports Second Quarter 2020 Financial Results Carlsbad, Calif. – September 17, 2020 – Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), today reported financial results for its second quarter ended June 30, 2020. Recent Highlights: • Reported revenue of $1.1 million in the second quarter of 2020, a 54% increase over the same quarter last year and wit |
|
| August 20, 2020 |
AFIB / Acutus Medical, Inc. / Flynn James E Activist Investment SC 13D 1 e619884sc13d-am.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13D-2(a) (Amendment No. )* Acutus Medical, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 005111109 (CUSIP Number) Dav |
|
| August 20, 2020 |
Joint Filing Agreement dated as of August 20, 2020 by and among the Reporting Persons.* EX-99.1 2 e619884ex99-1.htm Exhibit 99.1 The undersigned agree that this Schedule 13D, and all amendments thereto, relating to the Common Stock of Acutus Medical, Inc. shall be filed on behalf of the undersigned. DEERFIELD MGMT III, L.P. By: J.E. Flynn Capital III, LLC, General Partner By: /s/ Jonathan Isler Name: Jonathan Isler Title: Attorney-in-Fact DEERFIELD PRIVATE DESIGN FUND III, L.P. By: D |
|
| August 18, 2020 |
EX-99.1 2 ss179883ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated August 18, 2020, with respect to the ordinary shares of Acutus Medical, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the |
|
| August 18, 2020 |
AFIB / Acutus Medical, Inc. / ORBIMED ADVISORS LLC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Acutus Medical, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 065111109 (CUSIP Number) OrbiMed Advisors LLC OrbiMed ROF II LLC OrbiMed Capital GP IV LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, Address and Tel |
|
| August 10, 2020 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ACUTUS MEDICAL, INC. * * * * * Article 1 Offices Section 1.01. Registered Office. The registered office of the Corporation shall be in the City of Wilmington, County of New Castle, State of Delaware. Section 1.02. Other Offices. The Corporation may also have offices at such other places both within and without the State of Delaware as the Board of Directo |
|
| August 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2020 Acutus Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 001- 39430 45-1306615 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 10, 2020 |
Amended and Restated Certificate of Incorporation Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ACUTUS MEDICAL, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Acutus Medical, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: A. The name of the Corporation is Acutus Medical, Inc. The original Certificate of Inco |
|
| August 7, 2020 |
424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-239873 Registration No. 333-241091 8,823,529 Shares Common Stock This is the initial public offering of shares of common stock of Acutus Medical, Inc. We are offering 8,823,529 shares of our common stock. Prior to this offering, there has been no public market for our common stock. The initial public offering price per s |
|
| August 6, 2020 |
As filed with the Securities and Exchange Commission on August 5, 2020 Registration No. |
|
| August 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Acutus Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 45-1306615 (State of incorporation or organization) (I.R.S. Employer Identification No.) 2210 Faraday Ave., Suit |
|
| August 5, 2020 |
As filed with the Securities and Exchange Commission on August 5, 2020 Registration No. |
|
| August 3, 2020 |
CORRESP August 3, 2020 VIA EDGAR TRANSMISSION AND FEDEX U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Jenn Do Ms. Mary Mast Mr. Chris Edwards Mr. Joe McCann Re: Acutus Medical, Inc. Registration Statement on Form S-1 Registration No. 333-239873 Ladies and Gentlemen: In accordance with Rule 461 under the Securities A |
|
| August 3, 2020 |
CORRESP August 3, 2020 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| July 30, 2020 |
Form of Employment Agreement between the Registrant and Gary W. Doherty EX-10.23 8 d827177dex1023.htm EX-10.23 Exhibit 10.23 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is made by and amongst ACUTUS MEDICAL, INC. (the “Company”), having its principal offices at 2210 Faraday Ave., Suite 100 Carlsbad, CA 92008, and Gary Doherty (the “Executive”), effective as of [DATE] (the “Effective Date”). WHEREAS, the Company desires to employ the Executive in |
|
| July 30, 2020 |
2020 Equity Incentive Plan and forms of agreements thereunder. EX-10.14 Exhibit 10.14 ACUTUS MEDICAL, INC. 2020 EQUITY INCENTIVE PLAN (adopted on [ ], 2020; effective as of one business day immediately prior to the Registration Date) 1. Purposes of the Plan; Award Types. (a) Purposes of the Plan. The purposes of this Plan are to attract and retain personnel for positions with the Company Group, to provide additional incentive to Employees, Directors, and Cons |
|
| July 30, 2020 |
Specimen Common Stock Certificate EX-4.2 Exhibit 4.2 ACUTUS MEDICAL TM PO BOX 505006, Louisville, KY 40233-5006 MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 CUSIP/IDENTIFIER XXXXXX XX X Holder ID XXXXXXXXXX Insurance Value 1,000,000.00 Number of Shares 123456 DTC 12345678 123456789012345 Certificate Numbers 1234567890/1234567890 1234567890/1234567890 1234567890/1234567890 1234567890/1234567890 1234567890/1234567890 123 |
|
| July 30, 2020 |
S-1/A Table of Contents As filed with the Securities and Exchange Commission on July 30, 2020 Registration No. |
|
| July 30, 2020 |
Consent to be Named as a Director Nominee (Shaden Marzouk) EX-99.1 Exhibit 99.1 CONSENT TO BE NAMED AS A DIRECTOR NOMINEE In connection with the filing by Acutus Medical, Inc. of the Registration Statement on Form S-1, and in all subsequent amendments and post-effective amendments or supplements thereto, with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 o |
|
| July 30, 2020 |
Form of Employment Agreement between the Registrant and John Barnickel EX-10.24 Exhibit 10.24 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is made by and amongst ACUTUS MEDICAL, INC. (the “Company”), having its principal offices at 2210 Faraday Ave., Suite 100 Carlsbad, CA 92008, and John Barnickel (the “Executive”), effective as of [DATE] (the “Effective Date”). WHEREAS, the Company desires to employ the Executive in the position of Chief Commer |
|
| July 30, 2020 |
Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ACUTUS MEDICAL, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Acutus Medical, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: A. The name of the Corporation is Acutus Medical, Inc. The original Certificate of Inco |
|
| July 30, 2020 |
2020 Employee Stock Purchase Plan. Exhibit 10.15 ACUTUS MEDICAL, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Companies with an opportunity to purchase Common Stock through accumulated Contributions. The Company intends for the Plan to have two components: a component that is intended to qualify as an “employee stock purchase plan” under Section |
|
| July 30, 2020 |
EX-1.1 Exhibit 1.1 Acutus Medical, Inc. [●] Shares of Common Stock, par value $0.001 per share Underwriting Agreement August [●], 2020 J.P. Morgan Securities LLC BofA Securities, Inc. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 c/o BofA Securities, Inc. One Bryant Park New York, NY 10036 Ladies and |
|
| July 23, 2020 |
CORRESP FOIA Confidential Treatment Request Pursuant To Rule 83 by Acutus Medical, Inc. |
|
| July 15, 2020 |
2020 Equity Incentive Plan and forms of agreement thereunder EX-10.14 Exhibit 10.14 ACUTUS MEDICAL, INC. 2020 EQUITY INCENTIVE PLAN 1. Purposes of the Plan; Award Types. (a) Purposes of the Plan. The purposes of this Plan are to attract and retain personnel for positions with the Company Group, to provide additional incentive to Employees, Directors, and Consultants (collectively, “Service Providers”), and to promote the success of the Company’s business. ( |
